Investor Relations

Corporate Profile

Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.

Press Releases

Jun 11, 2021
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade Cytokine Release Syndrome observed Durability of response in ALL patients continues to support potential for
May 25, 2021
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells - LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plcĀ (Nasdaq: AUTL), a clinical-stage biopharmaceutical company


More events are coming soon.